FDA accepts Seattle Genetics' lymphoma drug Adcetris for review

05/16/2013 | Bloomberg Businessweek · PharmaTimes (U.K.)

The FDA has accepted Seattle Genetics' supplemental biologics license application for the use of Adcetris, or brentuximab vedotin, for retreatment and use beyond 16 cycles of therapy in patients with relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. A decision is expected by Sept. 14.

View Full Article in:

Bloomberg Businessweek · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY